Human myeloid dendritic cells for cancer therapy: does maturation matter?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Vaccine

• Publication date

  2010-07-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2010.05.042PMID 20665974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL‐23 and IL‐12p70 production by monocytes and dendritic cells in primary HIV‐1 infection

  2010cited by this paper
• [The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells].

  2009cited by this paper
• Activation of dendritic cells by toll-like receptors and C-type lectins.

  2009cited by this paper
• A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma

  2009cited by this paper
• Immune Responses in Patients with Metastatic Renal Cell Carcinoma Treated with Dendritic Cells Pulsed with Tumor Lysate

  2009cited by this paper
• Dendritic cells in rheumatoid arthritis: Which subset should be used as a tool to induce tolerance?

  2009cited by this paper
• Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.

  2009cited by this paper
• Generation of a Dendritic Cell‐based Vaccine in Chronic Lymphocytic Leukaemia Using CliniMACS Platform for Large‐scale Production

  2009cited by this paper
• IFN-alpha in the generation of dendritic cells for cancer immunotherapy.

  2009cited by this paper
• Harnessing Human Dendritic Cell Subsets to Design Novel Vaccines

  2009cited by this paper
• Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma: A Clinical Phase 1/2 trial

  2008cited by this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cited by this paper
• Combination of Cobe AutoPBSC and Gambro Elutra as a platform for monocyte enrichment in dendritic cell (DC) therapy: Clinical study

  2008cited by this paper
• Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

  2008cited by this paper
• Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes

  2008cited by this paper
• Dendritic cell vaccination and immune monitoring

  2008cited by this paper
• Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines

  2008cited by this paper
• Regulation of interleukin‐12/interleukin‐23 production and the T‐helper 17 response in humans

  2008cited by this paper
• Dendritic cells and cytokines in human inflammatory and autoimmune diseases.

  2008cited by this paper
• Dendritic cells in cancer immunotherapy.

  2008cited by this paper
• Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon‐γ (IFN‐γ)

  2008cited by this paper
• Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells

  2008cited by this paper
• Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration

  2008cited by this paper
• A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.

  2008cited by this paper
• Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient‐specific tumour idiotype protein or idiotype (VDJ)‐derived class I‐restricted peptides

  2007cited by this paper
• Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells

  2007cited by this paper
• Development of dendritic-cell lineages.

  2007cited by this paper
• Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70

  2007cited by this paper
• Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients

  2007cited by this paper
• Current approaches in dendritic cell generation and future implications for cancer immunotherapy

  2007cited by this paper
• Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.

  2007cited by this paper
• A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines

  2007cited by this paper
• Tolerogenic dendritic cells: cytokine modulation comes of age.

  2006cited by this paper
• Cross-Linking Cell Surface Chemokine Receptors Leads to Isolation, Activation, and Differentiation of Monocytes into Potent Dendritic Cells

  2006cited by this paper
• Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

  2006cited by this paper
• Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma

  2006cited by this paper
• Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.

  2006cited by this paper
• Isolation of monocytes from whole blood‐derived buffy coats by continuous counter‐flow elutriation

  2006cited by this paper
• Dendritic cells: translating innate to adaptive immunity.

  2006cited by this paper
• Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

  2006cited by this paper
• Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells

  2005cited by this paper
• Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

  2005cited by this paper
• Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1

  2005cited by this paper
• Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.

  2005cited by this paper
• Dendritic cells as therapeutic vaccines against cancer

  2005cited by this paper
• Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.

  2005cited by this paper
• Immunotherapy and chemotherapy — a practical partnership

  2005cited by this paper
• Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity1

  2005cited by this paper
• The Chemokine Receptor CCR7 Activates in Dendritic Cells Two Signaling Modules That Independently Regulate Chemotaxis and Migratory Speed1

  2005cited by this paper
• Dendritic cell fusion vaccines for cancer immunotherapy

  2005cited by this paper
• A type I interferon autocrine–paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells

  2005cited by this paper
• The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration1

  2005cited by this paper
• Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions.

  2005cited by this paper
• Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses

  2005cited by this paper
• Manipulating dendritic cell biology for the active immunotherapy of cancer.

  2004cited by this paper
• Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity

  2004cited by this paper
• Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

  2004cited by this paper
• alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

  2004cited by this paper
• Helping the CD8+ T-cell response

  2004cited by this paper
• Dendritic cell immunotherapy: mapping the way

  2004cited by this paper
• Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy.

  2004cited by this paper
• Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells

  2004cited by this paper
• Maturation of dendritic cells by bacterial immunomodulators.

  2004cited by this paper
• Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli.

  2003cited by this paper
• Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy.

  2003cited by this paper
• Large-Scale Immunomagnetic Selection of CD14+ Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study

  2003cited by this paper
• What it takes to become an effector T cell: The process, the cells involved, and the mechanisms

  2003cited by this paper
• Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells.

  2003cited by this paper
• T cell anergy.

  2003cited by this paper
• Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection.

  2003cited by this paper
• Regulation of dendritic cell function through toll-like receptors.

  2003cited by this paper
• Antigen presentation and T cell stimulation by dendritic cells.

  2002cited by this paper
• Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial

  2002cited by this paper
• Characterization of human blood dendritic cell subsets.

  2002cited by this paper
• Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance

  2002cited by this paper
• The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics.

  2001cited by this paper
• Sensing Pathogens and Tuning Immune Responses

  2001cited by this paper
• The cell biology of antigen presentation in dendritic cells.

  2001cited by this paper
• Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells

  2000cited by this paper
• Immunobiology of dendritic cells.

  2000cited by this paper
• Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma

  2000cited by this paper
• Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells

  2000cited by this paper
• BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood

  2000cited by this paper
• Mobilizing Dendritic Cells for Tolerance, Priming, and Chronic Inflammation

  1999cited by this paper
• T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal.

  1999cited by this paper
• Interleukin-12: a cytokine at the interface of inflammation and immunity.

  1998cited by this paper
• Dendritic cells: unique leukocyte populations which control the primary immune response.

  1997cited by this paper
• Dendritic Cells: Unique Leukocyte Populations Which Control the Primary

  1997cited by this paper
• Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

  1997cited by this paper
• Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions

  1997cited by this paper
• Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.

  1997cited by this paper
• Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.

  1997cited by this paper
• Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.

  1996cited by this paper
• Proliferating dendritic cell progenitors in human blood

  1994cited by this paper
• Inhibition of human macrophage colony formation by interleukin 4

  1989cited by this paper
• Human dendritic cells. Enrichment and characterization from peripheral blood

  1982cited by this paper
• Kinase-Mitogen-Activated Protein Kinase Signal-Regulated Modulation of Extracellular Distinct Th Responses via Differential Agonists Instruct Dendritic Cells to Induce Cutting Edge: Different Toll-Like Receptor

  year unknowncited by this paper

• Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy

  2024cites this paper
• Comprehensive FGFR3 alteration-related transcriptomic characterization is involved in immune infiltration and correlated with prognosis and immunotherapy response of bladder cancer

  2022cites this paper
• Combined effects of oncolytic vaccinia virus and dendritic cells on the progression of melanoma B16-F10 in mice

  2022cites this paper
• Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

  2019cites this paper
• Inmuno-monitoreo del componente de células presentadoras de antígeno (APC) y células T en distintos estadios del desarrollo de cáncer gástrico de tipo intestinal

  2019cites this paper
• Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia

  2019cites this paper
• Maturation and Antigen Loading Protocols Influence Activity of Anticancer Dendritic Cells

  2018cites this paper
• Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells

  2018cites this paper
• Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.

  2017cites this paper
• The Role of Mechanism of Action of CD200:CD200R1 Interaction in Breast Cancer

  2015cites this paper
• Immunotherapy for Acute Myeloid Leukemia.

  2015cites this paper
• Clinical perspectives in cancer vaccines for hematological diseases

  2015cites this paper
• Adenovirus-mediated overexpression of gamma interferon in murine bone marrow-derived dendritic cells affects their viability and activity

  2014cites this paper
• Preparation of dendritic cells for cancer immunotherapy

  2014cites this paper
• Antiviral Regulation in Porcine Monocytic Cells at Different Activation States

  2014cites this paper
• Cryptococcus gattii Is Killed by Dendritic Cells, but Evades Adaptive Immunity by Failing To Induce Dendritic Cell Maturation

  2013cites this paper
• Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: an in vitro study.

  2013cites this paper
• Dendritic cell subsets biology and application in cancer immunotherapy

  2013cites this paper
• Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy

  2013cites this paper
• Failing To Induce Dendritic Cell Maturation Cells, but Evades Adaptive Immunity by Is Killed by Dendritic Cryptococcus gattii

  2013cites this paper
• CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses

  2013cites this paper
• Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy.

  2012cites this paper
• CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells

  2012cites this paper
• Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

  2012cites this paper
• Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6

  2012cites this paper
• Effect of Nitric Oxide on Myeloid Dendritic Cell Adhesion A thesis presented to the faculty of the Russ College of Engineering and Technology of Ohio University In partial fulfillment of the requirements for the degree Master of Science

  2012influential citation
• Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy

  2012cites this paper
• CD200:CD200R-Mediated Regulation of Immunity

  2012cites this paper
• The Use of Human Dendritic Cell Subsets in Cancer Vaccines

  2011cites this paper
• Therapeutic Response in Patients with Advanced Malignancies Treated with Combined Dendritic Cell–Activated T Cell Based Immunotherapy and Intensity–Modulated Radiotherapy

  2011cites this paper
• Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432.

  2011cites this paper
• Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma

  2011cites this paper
• Isolation and Generation of Human Dendritic Cells

  1997cites this paper